NCT04503265
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations, BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous exposure to an anti-PD-1 or anti-PD-L1 inhibitor (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
https://ClinicalTrials.gov/show/NCT04503265